Loading…
← CockpitCompetitor Analysis › CRVS Corvus Pharmaceuticals, Inc.Open in the cockpit ↗

Corvus Pharmaceuticals, Inc.CRVSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 28
Mkt cap
$860M
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$10.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.9%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$10.19
1D+0.2%
1W-11.2%
1M-0.4%
3M-28.9%
6M-16.4%
YTD+32.3%
1Y+14.4%
ATR %6.7%
Beta-0.15
52w lowhigh62.2% off high

What Corvus Pharmaceuticals does

Employees: 37

Corvus Pharmaceuticals at a glance

Size Corvus Pharmaceuticals (CRVS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $860M, the 2320th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.19 on 18 Nov 2026.

Performance Over six months the shares fell 16.4%, against -22.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 19 in its peer set.

Short interest Short interest is 21.1% of the free float (30 Oct 2026).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026CRVS 78Peer median 78
Six months, rebased to 100: Corvus Pharmaceuticals against the median of its 20 peers (local-currency closes).

Corvus Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$184,000-$105,000-$85,000-$151,000-$367,000
EBITDA-$67.6M-$42.9M-$27.5M-$23.3M-$32.2M
Net income-$64.3M-$15.3M-$62.3M-$27.0M-$41.3M
Free cash flow-$47.9M-$33.0M-$25.4M-$24.0M-$27.3M
Capital expenditure$764,000$174,000$0$34,000$269,000
Total debt$632,000$937,000$1.12M$1.37M$2.60M

Quarterly statements and history in the cockpit →

Corvus Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%4521069620086450688176600771006120PHARMSANOFICONR688621300267000597000813AKTS60322900208268855360782595CRVS6-month return →1-month return →
Up and to the right = strong over both horizons. Corvus Pharmaceuticals is the large dot.

Corvus Pharmaceuticals competitors and peer comparison

How Corvus Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Corvus Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureCRVSPeer medianRank in peer set
1-month return-0.4%-10.5%6th highest of 21
6-month return-16.4%-22.8%9th highest of 19
Distance from 52-week high-62.2%-40.2%3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a

Questions

Which companies are Corvus Pharmaceuticals's closest peers?
The cockpit's peer set: Kaken Pharmaceutical (4521.T), City Therapeutics (CTY), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS), Jiangsu Yahong Meditech (688176.SS), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS), Pharming (PHARM.AS).
How has Corvus Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -16.4% against -22.8% for the median peer; over one year +14.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.